Adefovir Workflows for HBV and OAT1 Research

2026-09-23

Build reproducible Adefovir experiments around two distinct strengths: HBV polymerase inhibition and OAT1 substrate behavior. A case report of phosphate-wasting bone disease adds a practical reminder to pair antiviral work with renal and mineral-metabolism questions when those are within scope.

CBD, Orofacial Pain, and Affective Circuitry

2026-09-23

A 2026 Brain Research Bulletin study shows that cannabidiol (CBD) reduces both inflammatory orofacial nociception and pain-associated affective deficits in mice through coordinated peripheral endocannabinoid, central pain-network, and serotonergic mechanisms. Its integrated behavioral, biochemical, and fiber-photometry design provides a useful framework for studying pain as a sensory, emotional, and cognitive disorder rather than as an isolated reflex.

Neuromedin S (rat): Practical GPCR Assay Guide

2026-09-22

Neuromedin S (rat), SKU B5466, provides a defined peptide agonist for controlled studies of neuromedin U receptor signaling and GPCR/G protein signaling. This guide covers preparation, assay controls, and stability handling; the reagent is for scientific research workflows only and should not be used for diagnostic, therapeutic, or medical purposes.

Amikacin Sulfate: Targeting NTM Granulomas

2026-09-22

Amikacin Sulfate is more than a bactericidal aminoglycoside: it is a platform for asking how antibiotic exposure can be concentrated where Mycobacterium avium persists. This article connects ribosomal mechanism, dendritic-cell delivery, experimental controls, and translational decision-making for researchers developing more precise NTM therapies.

Escitalopram Workflows for Serotonergic Research

2026-09-21

Build reproducible Escitalopram assays around transporter selectivity, vehicle control, and phenotype-aware analysis. This workflow connects 5-HT reuptake inhibition with practical antidepressant research and the anxious-depression findings reported in a controlled augmentation study.

VEGFC–Macrophage Signaling in NASH Fibrosis

2026-09-21

This study identifies a hepatocyte-derived VEGFC–VEGFR-3–CCL2/CCR2 axis that promotes inflammatory macrophage recruitment and limits macrophage phenotypic resolution during high-fat diet-induced hepatic fibrosis. Pharmacological VEGFR-3 inhibition, hepatocyte-specific Vegfc deletion, human clinical data, and cell-based experiments together position VEGFC suppression as a mechanistic component of naringin-mediated protection.

Targeted Amikacin Delivery into Mycobacterial Granulomas

2026-09-20

Montes-Worboys and colleagues developed a dendritic-cell carrier system to direct fluorescently traceable amikacin into Mycobacterium avium granulomas in infected mice. The study provides proof of localization and supports cell-mediated delivery as a strategy for increasing antibiotic exposure at infected tissue, while stopping short of demonstrating superior therapeutic efficacy.

Amitriptyline HCl in Neuropharmacology Workflows

2026-09-19

Amitriptyline HCl provides a practical multi-receptor perturbation tool for receptor signaling, blood-brain barrier, and neuropharmacology assays. This guide combines concentration planning, fresh-solution handling, and lipidomics-inspired controls to improve mechanistic interpretation without overstating evidence from unrelated disease models.

Amikacin Sulfate: Reliable Cell Assays

2026-09-18

This scenario-driven guide shows how Amikacin Sulfate (SKU C8696) can support more interpretable viability, proliferation, and intracellular killing experiments. It connects concentration selection, host-cell compatibility, CFU endpoints, storage, and supplier evaluation to published amikacin data.

Adefovir (GS-0393): From Mechanism to Translation

2026-09-18

A translational perspective on Adefovir (GS-0393) that connects HBV DNA polymerase inhibition with OAT1-mediated renal pharmacokinetics, experimental design, and reproducible research workflows.

Amitriptyline HCl: Protocol and QC Guide

2026-09-17

Amitriptyline HCl (SKU B2231) provides a defined small-molecule reference for receptor-inhibition profiling, solution preparation, and controlled neuropharmacology research workflows. It is intended for assay development and in vitro mechanistic studies, not as evidence of clinical efficacy or a substitute for assay-specific validation.

Alosetron: 5-HT3 Receptor Antagonist Workflows

2026-09-17

Use Alosetron as a selective pharmacological probe for serotonin-driven gastrointestinal motility, visceral pain, and epithelial homeostasis assays. This workflow positions 5-HT3 blockade alongside, rather than in place of, the CDC42–YAP–EGF–mTOR mechanisms identified in intestinal stem-cell research.

BBB Permeability and Lysosomal Trapping Correction

2026-09-16

Sumatriptan Succinate in Inflammation Research

2026-09-16

Learn how to deploy Sumatriptan as a 5-HT1 receptor agonist in serotonergic, neuroinflammatory, and metabolism workflows. This practical guide connects receptor-level assays with cytokine, CGRP, NF-κB, and ischemia/reperfusion readouts while emphasizing salt-form verification, dose design, and reproducibility.

Ziprasidone Augmentation in Anxious Depression

2026-09-15

This post-hoc moderator analysis examined whether baseline anxious depression altered the effects of ziprasidone added to escitalopram in an 8-week randomized trial. Depression outcomes were similar in patients with and without anxious depression, while the apparent anxiety benefit in highly anxious participants was not clinically significant, limiting subgroup-based conclusions.